Schedule III's First Week in the Wild: Operators File With the DEA, Germany Breaks Records, and a Lawsuit Drops

Schedule III's First Week in the Wild: Operators File With the DEA, Germany Breaks Records, and a Lawsuit Drops

The ink on the most consequential federal cannabis policy shift in a generation is barely dry, and the industry is already sorting itself into winners, fast movers, and skeptics. Two weeks after the Department of Justice issued its April 23 Final Order reclassifying state-licensed medical cannabis to Schedule III of the Controlled Substances Act, the week of May 4–10 offered the first real glimpse of how operators are navigating a regulatory landscape that still has more question marks than answers.

The DEA opened its Medical Marijuana Dispensary Registration Portal on April 29, and companies began flooding it with applications this week. Green Thumb Industries and Glass House Brands both publicly announced filings through the expedited 60-day window, under which applicants are permitted to continue operating while the DEA processes their paperwork. Trulieve, one of the largest medical-focused multistate operators in the country, had already announced its intent to register earlier in the rescheduling announcement cycle. The message from all three companies was consistent: moving quickly is both a compliance necessity and a competitive signal. Companies that register earn legitimacy; those that don't may find themselves caught between two legal frameworks simultaneously.

That compliance scramble is just one dimension of the rescheduling aftermath. The other — equally significant for long-struggling operators — is the question of taxes. For years, cannabis companies have operated under the punishing strictures of IRS code Section 280E, which bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. With state-licensed medical cannabis now sitting in Schedule III, those deductions become available, at least for the medical segment of operations. For companies like Trulieve that are heavily concentrated in medical markets, the tax implications alone could meaningfully change profitability projections heading into 2027.

The broader rescheduling story, however, remains unfinished. The Final Order covers only FDA-approved products and state-licensed medical cannabis — adult-use recreational operations remain in Schedule I limbo for now. A formal DEA hearing to consider broader rescheduling of all marijuana is scheduled for June 29, and interested parties have until May 28 to submit written notice of participation. That hearing will be a pivotal moment: it will determine whether recreational cannabis eventually follows the same path, or whether the bifurcation between medical and adult-use becomes a permanent feature of the federal landscape.

Across the Atlantic, the rescheduling backdrop is adding momentum to an already surging European cannabis trade. This week, High Tide Inc. reported that its 51%-owned German subsidiary, Remexian Pharma GmbH, sold 7.6 tonnes of medical cannabis into the German market in the second fiscal quarter ended April 30, 2026 — the highest quarterly distribution volume in the subsidiary's history. That figure represents a 21% sequential increase and a 49% jump year-over-year, a rate of growth that speaks to just how quickly Germany's medical market is expanding following its 2024 partial legalization reforms. Germany imported 201.1 tonnes of medical cannabis in 2025, more than double the 72.9 tonnes imported the year before, and Canadian producers — who supply nearly half of Germany's imports — are racing to meet that demand.

The Remexian milestone comes in the same month that Tilray Brands completed its acquisition of Lyphe Group, one of the UK's longest-established medical cannabis clinics and digital pharmacy platforms. The deal — the largest North American acquisition of a European cannabis player in years — marks Tilray's second UK acquisition of 2026, and it signals the company's ambition to build a fully vertically integrated European healthcare platform. Lyphe has dispensed approximately 150,000 units to date and treated more than 16,000 patients; folded into Tilray Medical's existing pharmaceutical-grade cultivation and distribution operations, the combined platform represents a serious institutional bet on European medical cannabis as a long-term growth market.

Back in the United States, the week also brought legal turbulence. A class action federal lawsuit was filed against three prominent multistate operators — Cresco Labs, Green Thumb Industries, and Verano Holdings — alleging that the companies make false claims about the medical benefits of their products while downplaying associated risks. The lawsuit, filed in federal court in Chicago, adds a new and complicated wrinkle to an industry that is simultaneously celebrating its first federal legitimacy and fighting to establish consumer trust.

On the pricing front, wholesale cannabis flower markets showed modest but meaningful divergence during the week. The U.S. Cannabis Spot Index closed at $1,056 per pound on May 8, with the June implied forward at $1,090 — a 3.2% premium suggesting slight optimism about near-term demand. Pennsylvania stood out, with its state index rising 7.6% per pound to reach its highest level since the opening week of the year. Maine also ticked upward. California, however, continued its downward drift, falling to its lowest level since February.

The picture that emerges from this week is one of an industry in simultaneous motion — companies hustling to comply with new rules, exploring new markets, defending themselves in court, and watching their margins shift in real time. The rescheduling era has officially begun, and whatever it looks like in a year, it is clearly already reshaping how and where cannabis money flows.